Biopharma · FDA Approvals · Stock

SLDB Solid Biosciences

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular ta…

Assets on file: SGT-003

Start live analysis of SLDB Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for SLDB, including recently decided ones.

May 2027

May 6, 2027

in 187 days

SLDBSolid Biosciences

SGT-003: Phase 1/Phase 2 trial NCT06138639 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

January 2029

Jan 2029

~ Jan 2029

SLDBSolid Biosciences

SGT-003: Phase 3 trial NCT07160634 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for SLDB, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Nov 3, 2025

10:15 PM

SLDBSolid Biosciences

SLDB: INSPIRE DUCHENNE interim data; FDA meeting planned H1 2026

The 8-K reports positive interim Phase 1/2 data from 23 participants showing mean 58% microdystrophin expression and strong correlations with DAPC restoration and muscle-protection biomarkers. The company has advanced its planned FDA meeting to H1 2026 to discuss potential registrational pathways, including accelerated approval, after dosing 30 participants and initiating IMPACT DUCHENNE Phase 3 ex-U.S.

Topline resultsSEC 8-K Open record